Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7247669 in previously untreated unresectable or metastatic melanoma
NCT05419388Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2022
- Primary completion
- May 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of tobemstomig in melanoma, sponsored by Roche. Started Aug 2022; status: completed.
02
Drugs
tobemstomig
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05419388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419388.